Generic drug for wellbutrin
Larry Hsu, Ph. , President of IMPAX, said, This application complements our previous ANDAs for Bupropion HCl 100mg and 150mg Extended Release Tablets. Food and Drug Administration (FDA) under Paragraph IV of the Hatch-Waxman Amendments, stating that it believes its generic versions of Wellbutrin XL 150 and generic drug for wellbutrin 300 mg tablets do not infringe Biovail’s listed patents or that the listed patents are invalid or unenforceable. We expect to reach our objective of filing six new applications in 2003, said Larry Hsu, Impax’s president. Such risks and uncertainties include, but are not limited to, IMPAX’s ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX’s ability to successfully develop and commercialize pharmaceutical products, IMPAX’s reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX’s filings with the Securities and Exchange Commission. Sales of 200 mg Wellbutrin tablets in 2002. About Biovail Corporation Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical generic drug for wellbutrin products utilizing advanced drug-delivery technologies. Food and Drug Generic drug for wellbutrin administration. Glaxo Wellcome markets Wellbutrin SR for the treatment of depression and markets Zyban as an aid in smoking cessation. Biovail applies its time-release drug-delivery systems to existing drugs that treat a variety of conditions such as hypertension, asthma, and arthritis. The FDA also awarded the Company first-to-file status and 180-day market exclusivity for this product. Biovail continues to develop a generic drug for wellbutrin new once-daily bupropion formulation. (Nasdaq:IPXL) today announced that the U. Branded product generic drug for wellbutrin sales for the twelve months ended December 31, 2003. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements Generic drug for wellbutrin made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. For more information, please visit the Company’s Web site at: www. Impaxlabs. For more information regarding Mylan Laboratories Inc. , we invite you to visit our corporate web site at www. GENERIC COMPETITION is the buzz phrase worrying the bigpharma companies at the Generic drug for wellbutrin moment. Sales of Wellbutrin SR by GlaxoSmithKline have generated about $1. 2 billion annually